Merck & Co Resumes Islatravir HIV Studies After Safety Concerns, But Abandons PrEP Approach

Maintains Belief In Oral Long-Acting Regimen

 
• By Andrew McConaghie
  
Merck
Merck is trying to get its long-acting HIV program back on track, but is lagging behind GSK and Gilead • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D